{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["89"],"submitter":["Joshi SR"],"pubmed_abstract":["<h4>Background</h4>There is an unmet need for antiretrovirals with novel mechanisms of action that can provide additional options for people with HIV-1. DOMINO evaluated the efficacy and safety of the maturation inhibitor GSK3640254 (GSK'254) plus two nucleoside reverse transcriptase inhibitors (NRTIs) in adults naive to antiretroviral therapy.<h4>Methods</h4>This partially blinded, multicentre phase 2b trial enrolled people with HIV-1 from 54 centres in ten countries (Argentina, Canada, France, Germany, Italy, Portugal, Russian Federation, South Africa, Spain, and the United States). Eligible participants were adults with plasma HIV-1 RNA ≥1000 copies/mL and CD4+ T-cell count ≥250 cells/mm<sup>3</sup> who were naive to antiretroviral therapy. Participants were centrally randomised to rece"],"journal":["EClinicalMedicine"],"pagination":["103567"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12675029"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study."],"pmcid":["PMC12675029"],"pubmed_authors":["Joshi SR","Chernova OE","Fishman C","Nunez SA","Cordova E","Jeffrey JL","Joshi A","Lataillade M","Bainbridge V","Oyee J","Mitha E","Zhang Y","Man C","Potthoff A","Ramgopal M","Llibre JM","Castagna A","Wynne B"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study.","description":"<h4>Background</h4>There is an unmet need for antiretrovirals with novel mechanisms of action that can provide additional options for people with HIV-1. DOMINO evaluated the efficacy and safety of the maturation inhibitor GSK3640254 (GSK'254) plus two nucleoside reverse transcriptase inhibitors (NRTIs) in adults naive to antiretroviral therapy.<h4>Methods</h4>This partially blinded, multicentre phase 2b trial enrolled people with HIV-1 from 54 centres in ten countries (Argentina, Canada, France, Germany, Italy, Portugal, Russian Federation, South Africa, Spain, and the United States). Eligible participants were adults with plasma HIV-1 RNA ≥1000 copies/mL and CD4+ T-cell count ≥250 cells/mm<sup>3</sup> who were naive to antiretroviral therapy. Participants were centrally randomised to rece","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-05T23:37:20.173Z","creation":"2026-05-23T03:13:50.268Z"},"accession":"S-EPMC12675029","cross_references":{"pubmed":["41357330"],"doi":["10.1016/j.eclinm.2025.103567"]}}